Search Results - "VIAZIS, N."

Refine Results
  1. 1

    Large Balloon Dilation vs. Mechanical Lithotripsy for the Management of Large Bile Duct Stones: A Prospective Randomized Study by STEFANIDIS, G, VIAZIS, N, KATSIKANI, A, CHUTTANI, R, PLESKOW, D, MANOLAKOPOULOS, S, THEOCHARIS, L, CHRISTODOULOU, C, KOTSIKOROS, N, GIANNOUSIS, J, SGOUROS, S, RODIAS, M

    Published in The American journal of gastroenterology (01-02-2011)
    “…The removal of large bile duct stones (>12 mm) after endoscopic sphincterotomy (EST) remains a challenging issue in therapeutic endoscopy. The aim of this…”
    Get full text
    Journal Article
  2. 2

    Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis by VLACHOGIANNAKOS, J., SAVERIADIS, A. S., VIAZIS, N., THEODOROPOULOS, I., FOUDOULIS, K., MANOLAKOPOULOS, S., RAPTIS, S., KARAMANOLIS, D. G.

    Published in Alimentary pharmacology & therapeutics (01-05-2009)
    “…Summary Background  Endotoxaemia is commonly seen in cirrhotic patients with ascites and this may be associated with increased portal pressure. Aim  To…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6

    Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission by Viazis, N, Pontas, C, Manolakis, A, Karampekos, G, Tsoukali, E, Galanopoulos, M, Koustenis, K, Archavlis, E, Christidou, A, Gazouli, M, Mantzaris, G J

    Published in Acta gastro-enterologica belgica (01-07-2021)
    “…Intravenously administered biologicals are associated with a huge pressure to Infusion Units and increased cost. We aimed to assess the impact of switching…”
    Get more information
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Somatostatin and its analogues in peptic ulcer bleeding: Facts and pathophysiological aspects by Sgouros, S.N., Bergele, C., Viazis, N., Avgerinos, A.

    Published in Digestive and liver disease (01-02-2006)
    “…Peptic ulcer bleeding remains a common medical emergency and despite recent advances in management is still associated with high mortality. Endoscopic…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    P723 Upadacitinib in Crohn’s disease: Real world experience from an early access program in Greece by Papathanasiou, E, Leonidakis, G, Michalopoulos, G, Manolakopoulos, S, Siakavellas, S, Theodoropoulou, A, Tasovasili, A, Giouleme, O, Tzouvala, M, Tsironi, E, Viazis, N, Michopoulos, S, Zampeli, E

    Published in Journal of Crohn's and colitis (24-01-2024)
    “…Abstract Background Upadacitinib is a novel selective Janus kinase 1 inhibitor, recently approved for the management of Crohn’s disease (CD) by Food and Drug…”
    Get full text
    Journal Article
  18. 18
  19. 19

    P429 Mesalazine has no place in the treatment of Crohn’s disease. Really? by Mantzaris MD- PhD- AGAF- FEBG- MACG, G, Archavlis, E, Christidou, A, Viazis, N, Karampekos, G

    Published in Journal of Crohn's and colitis (21-01-2022)
    “…Abstract Background According to international guidelines mesalazine may have no place in the treatment of Crohn’s disease (CD). However, real-world studies…”
    Get full text
    Journal Article
  20. 20